Patent Law Weblog
recent posts
- Constellation Designs, LLC v. LG Electronics Inc. (Fed. Cir. 2026)
- Actelion Pharmaceuticals Ltd. v. Mylan Pharmaceuticals Inc. (Fed. Cir. 2026)
- PTAB Reverses § 101 Rejection Where Examiner Failed to Follow the Office’s Own Guidance
- Collision Communications v. Samsung: What Good Did the Government’s Statement of Interest Do?
- United States Files Statement of Interest in Patent Infringement Proceedings
about
Month: April 2010
-
American Conference Institute (ACI) will be holding a conference on Follow-on Biologics on June 21-22, 2010 in New York, NY. ACI faculty will help attendees: • Prepare for follow-on patent litigation and understand what mechanisms are and will be in place for resolving patent disputes;• Analyze the impact of the 12-year exclusivity period on the…
-
Strafford will be offering a webinar entitled "Patents and the Written Description Requirement: Meeting Section 112 Disclosure Obligations After Ariad v. Lilly" on June 10, 2010 from 1:00 – 2:30 PM (EST). Peter Pappas of Sutherland Asbill & Brennan will provide guidance to patentees, patent challengers, and counsel for dealing with the written description requirement…
-
By Donald Zuhn — On Wednesday, less than a week before the industry congregates in Chicago for the 2010 BIO International Convention, Ernst & Young issued its 24th annual report on the biotech sector. In the report, entitled "Beyond Borders: Global Biotechnology Report 2010," the professional services firm concludes that "[t]he global biotechnology industry…
-
By Sarah Fendrick — The Enhanced First Action Interview Pilot Program, first implemented on October 20, 2009, was extended an additional six months beyond the original ending date of April 1, 2010. The program permits applicants to conduct an interview with an examiner after review of a pre-interview communication that discloses the results of…
-
By Donald Zuhn — On Monday, the Court of Appeals for the Federal Circuit decided that the appeal in Therasense, Inc. v. Becton, Dickinson & Co. warrants en banc consideration. In the Court's per curiam order, it noted that the panel that heard the appeal considered the petition for rehearing submitted by Plaintiffs-Appellants Abbott…
-
By Sarah Fendrick — In a notice published in the Federal Register (75 Fed. Reg. 19558), the U.S. Patent and Trademark Office cancelled Rule 41.200(b) as a result of the decision rendered in Agilent Technologies, Inc. v. Affymetrix, Inc., 567 F.3d 1366 (Fed. Cir. 2009). 37 C.F.R. § 41.200(b) (2004) provides: ''A claim shall…
-
By James DeGiulio — On April 13, 2010, Sloning Biotechnology announced the issuance of U.S. Patent No. 7,695,906, which covers an optimized method of Slonomics, the company's platform technology. Slonomics uses a set of double stranded DNA triplets as universal building blocks for the synthesis of combinatorial libraries. This triplet library contains all possible…
-
By Kevin E. Noonan — On April 14th, the Federal Circuit rendered a decision construing statutory language in a rather straightforward and unremarkable (albeit not unanimous) opinion. But the statutory language at issue involved the 2003 Medicare Prescription Drug Improvement and Modernization Act, which amended the 1984 Drug Price Competition and Patent Term Restoration…
-
Last week, Patent Docs published a post on the recent White Paper issued from the U.S. Patent and Trademark Office regarding provisions contained in the "Managers' Amendment" of the Senate patent reform bill (S. 515) (see "USPTO White Paper Supports Patent Reform Proposals"). The first author of that Paper, Ms. Arti Rai (at right), Administrator…
-
By Sherri Oslick — About Court Report: Each week we will report briefly on recently filed biotech and pharma cases. Ferndale Laboratories, Inc. v. PruGen, Inc. et al.2:10-cv-11644; filed April 22, 2010 in the Eastern District of Michigan • Plaintiff: Ferndale Laboratories, Inc.• Defendants: PruGen, Inc.; IGI Laboratories, Inc. Infringement of U.S. Patent No.…
Patent Docs 